Hsinchu, Taiwan – March 3, 2026 – OBIGEN PHARMA INC. (Ticker: 7876.TWO), Taiwan’s first botulinum toxin innovator, today announced that Phase II clinical data for OBI-858, its novel long-acting botulinum toxin type A candidate, has been accepted for E-Poster presentation at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2026, taking place 26–28 March 2026 in Monaco (Location: Grimaldi Forum Monaco Level -2 between Auditoria Camille Blanc and Prince Pierre from 09:00-18:00).
AMWC is widely regarded as the leading global congress for aesthetic and anti-aging medicine, bringing together physicians, industry leaders, and strategic partners from more than 120 countries to showcase late-breaking innovation and clinical advances in aesthetics, dermatology, and regenerative medicine.
The accepted E-poster, entitled:
“Onset and Duration Profiles of Novel Botulinum Toxin Type A Complexes: A Phase 2 Clinical Study on 760 kDa Formulations in Glabellar Line Treatment”,
will present detailed results from OBIGEN’s randomized, double-blind, placebo-controlled Phase II study evaluating the efficacy, safety, and duration of effect of OBI-858 in patients with moderate-to-severe glabellar lines (1).
Key Phase II findings to be presented at AMWC include:
These data were recently published in the peer-reviewed journal Dermatology and Therapy (2), further validating OBI-858’s differentiated clinical profile as a next-generation, long-acting botulinum toxin candidate.
OBI-858 is the world’s first botulinum toxin product characterized by a 760 kDa molecular structure, distinct from conventional 900 kDa formulations. The product is designed to deliver faster onset and extended duration while maintaining a favorable safety profile. OBI-858 is also Halal-certified, with a manufacturing process free from animal-derived materials and alcohol.
The AMWC 2026 presentation follows OBIGEN’s recent initiation of a 600-patient Phase III pivotal trial in Taiwan (3) for the aesthetic glabellar lines indication, positioning OBI-858 for future regulatory submissions and global partnering discussions. OBIGEN has also received acceptance from the U.S. Food and Drug Administration (FDA) for its Phase II Investigational New Drug (IND) application for OBI-858 in the glabellar lines indication, enabling U.S. clinical development (4).
Industry estimates project continued strong growth in the global botulinum toxin market over the coming decade, driven by increasing demand for minimally invasive aesthetic procedures and interest in longer-lasting formulations. Long-acting formulations are expected to become the new standard, creating a significant opportunity for OBI-858 to capture market share through strategic partnerships.
OBIGEN, together with its global partnering advisor KYBORA, will be available during AMWC 2026 to engage in strategic discussions with potential regional and global partners regarding the development and commercialization of OBI-858.
Why Partner with OBIGEN?
For partnership inquiries, please contact:
Patricia Chou
OBIGEN PHARMA INC.
Chief Executive Officer
Email: patriciachou@obigenpharma.com
Website: https://www.obigenpharma.com
Additional partnering contact:
Dr. Jean Chatellier, PhD
KYBORA (Global Partnering Advisor)
Partner, Executive Vice President & Senior Managing Director
Email: jean@kybora.com
Website: https://kybora.com
About OBIGEN PHARMA INC. – OBIGEN PHARMA INC. is Taiwan’s first biotechnology company dedicated to the research, development, and manufacturing of botulinum toxin products. Leveraging proprietary strain selection, advanced fermentation, and high-purity protein isolation technologies, OBIGEN has built a fully integrated value chain from API production to sterile injectable formulation. Our flagship product, OBI-858, is a next-generation, long-acting botulinum toxin with a unique 760 kDa molecular structure, designed to deliver faster onset, longer duration, and improved safety. Supported by a robust global IP portfolio, Halal certification, and PIC/S GMP-compliant facilities, OBIGEN is positioned to expand across Asia, the Middle East, the U.S., Latin America, and Europe through strategic partnerships and licensing opportunities.
About KYBORA – KYBORA is a global advisory firm and investment bank whose mission is to guide transformative healthcare companies to enduring success globally. We provide M&A, licensing, fundraising, and strategic advisory services to the global healthcare industry, creating value for our clients worldwide. With offices in the US, Switzerland, and China, and a direct presence in all key biopharma markets around the world, KYBORA offers unparalleled global reach and local knowledge.
About AMWC – The Aesthetic & Anti-Aging Medicine World Congress (AMWC) is the world’s leading scientific conference dedicated to aesthetic and anti-aging medicine, combining high-level education with a global platform for innovation, networking, and industry collaboration.
(1) AMWC e-poster will be available via the AMWC mobile application and on-site digital displays. Location: Grimaldi Forum Monaco Level -2 between Auditoria Camille Blanc and Prince Pierre from 09:00-18:00. https://www.amwc-conference.com/en/home.html
(2) Yen, YH., Tsau, TW., Lee, CH.et al. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OBI-858 for the Treatment of Moderate-to-Severe Glabellar Lines. Dermatol Ther (Heidelb) 15, 3717–3731 (2025). https://doi.org/10.1007/s13555-025-01561-5
(3) January 7, 2026 - OBIGEN PHARMA Inc. Launches Phase III Clinical Trial of World’s First 760 kDa Long-Acting Botulinum Toxin OBI-858 in Taiwan https://www.obigenpharma.com/en/announcements/announcements-16
(4) February 9, 2026 - OBIGEN PHARMA Inc. Announces U.S. FDA Acceptance of Phase II IND for OBI-858 in Aesthetic Glabellar Lines https://www.obigenpharma.com/en/announcements/announcements-17